Founder and CEO Waqaas Al Siddiq and members of Biotricity’s management team will attend the bell opening ceremony on Thursday, October 7, 2021 at 9:30 a.m.ET

REDWOOD CITY, CA / ACCESSWIRE / October 6, 2021 /Biotricity Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will ring the opening bell on the Nasdaq stock market on Thursday, October 7, 2021 at 9:30 am ET Founder and CEO Waqaas Al-Siddiq will attend the bell opening ceremony alongside members of the Biotricity team.

Since August, Biotricity has finalized financing to support sales expansion while minimizing dilution and maximizing shareholder value, listed on the Nasdaq stock exchange, and unveiled the expansion of its telehealth product portfolio, which increases the the company’s total addressable market with a stand-alone product that operates independently or in conjunction with its core offering.

The ringing event can be viewed on the Nasdaq live stream: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

A replay of the ceremony will be available later on the Biotricity investor relations site.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap between remote monitoring and chronic care management. Physicians and patients trust Biotricity’s unmatched standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic disease. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

All statements in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “may”, “should”, “would”, “will”, “could”, “,” “Expect”, “anticipate”, “estimate”, “believe”, “intend”, “seek”, “project” or “objective” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) management’s plans, objectives and goals for future operations, including plans, objectives or goals relating to the design, development and marketing of Bioflux or any other Company project products or services, (ii) a projection of revenues (including income / losses), profits (including profits / losses) per share, capital expenditure, dividends, capital structure or other financial elements, (iii) the future financial performance of the Company, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions under -joining or relating to any declaration described in points (i), (ii), (iii) or (iv) above. These forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances and may not be made because they are based on current projections, plans, objectives, beliefs, expectations, estimates and assumptions. of the Company and are subject to a number of risks and uncertainties and other influences, over which the Company has no control. The actual results and timing of certain events and circumstances may differ materially from those described in forward-looking statements due to these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the inability of the Company to obtain additional funding, the length of time and significant resources associated with the development of its products and the resulting insufficient cash flow and resulting illiquidity, the Company’s inability to develop its business, significant government regulation of medical devices and healthcare sector, lack of product diversification, existing or increased competition, results of arbitration and litigation, volatility and illiquidity of shares and the Company’s inability to implement its business plans. business or its strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this press release.

###

Media contact
Bospar
prforbiotricity@ bospar.com

Investor Relations
Biotricity Inc.
1-800-590-4155
[email protected]

THE SOURCE: Biotricity, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/666982/Remote-Medical-Diagnostic-Company-Biotricity-to-Ring-the-Nasdaq-Stock-Market-Opening-Bell-on-Thursday-October-7th